NEURONETICS INC

Neuronetics insider buying signals confidence: CEO, executive purchases amid volatile shares and Phase‑III neuro‑disorder trial—potential upside ahead.

Neuronetics insider buys signal confidence amid rising neuro‑health hype, suggesting potential upside if FDA approvals and market expansion materialize.

Neuronetics insider selling: CFO’s tax‑related RSU exit, CEO and EVP trades, but buying continues—insiders stay confident in the biotech’s future.

Insider buying boosts confidence in Neuronetics’ NeuroStar TMS device, showing strong efficacy for depression, low risk, and FDA expansion into OCD.

Insider buying of Neuronetics shares at $1.16 signals confidence amid a 73 % decline—why Jorey’s purchase may hint at undervaluation and future upside.

Insider sales at Neuronetics show routine tax‑planning, not distress, amid steady cash flow and neutral market sentiment.

Neuronetics insider sales reveal tax‑driven moves, not a bearish signal—CEO keeps 15 % stake while market volatility rises.

Insider sales at Neuronetics are routine tax moves, not a sign of doubt—yet investors must watch future trades, reimbursement deals and tech progress for hidden risks.